MedTrace Logo

Probiotics for Gout / Hyperuricemia: A Randomized, Intervention, Parallel Controlled, Multicenter Clinical Trial

NCT04199325 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2023-07-20

No results posted yet for this study

Summary

Under the premise of double-blind and non-interference clinical treatment, to evaluate the clinical efficacy and safety of probiotic Lactobacillus Zhang combined with routine treatment for gout hyperuricemia.

Conditions

  • Gout
  • Hyperuricemia

Interventions

DIETARY_SUPPLEMENT

Probiotics

Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.

DRUG

uric-acid-lowering drug

Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.

Sponsors & Collaborators

  • Inner Mongolia University of Science and Technology

    collaborator OTHER

  • Inner Mongolia Hulunboir hospital

    collaborator UNKNOWN

  • Inner Mongolia People's Hospital

    collaborator OTHER

  • Inner Mongolia Ordos Central Hospital

    collaborator UNKNOWN

  • Inner Mongolia Baogang Hospital

    collaborator OTHER

  • Inner Mongolia Medical College

    collaborator UNKNOWN

  • The Affiliated Hospital of Inner Mongolia Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2023-12-31
Completion
2024-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04199325 on ClinicalTrials.gov